Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2019-05-10 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
关于延期回复上海证券交易所问询函的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from 哈药集团股份有限公司 regarding a delay in responding to an inquiry letter from the Shanghai Stock Exchange about the company's 2018 annual report and 2019 first quarter report. It states the company will delay its reply and disclose it later. The document does not contain any financial data or the reports themselves, but is an announcement about the timing of a regulatory response. The length is only 557 characters, indicating it is a brief notice rather than a full report. Therefore, it fits best as a Regulatory Filing (RNS) since it is a compliance-related announcement that does not fit other categories.
2019-05-10 Chinese
关于控股股东哈药集团增资扩股事宜的进展公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the progress of a capital increase and share expansion by the controlling shareholder, Ha Yao Group. It mentions the submission of the plan to government authorities for approval and states that the company will disclose further information as the matter progresses. The document is only 403 characters long and does not contain detailed financial data or a full report. It is an update on financing activities, specifically about capital structure changes, but not a full capital/financing report. Given the content and length, it fits best under Capital/Financing Update (CAP).
2019-04-30 Chinese
关于延期回复上海证券交易所问询函的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Harbin Pharmaceutical Group Co., Ltd. regarding a delay in responding to an inquiry letter from the Shanghai Stock Exchange about the company's 2018 Annual Report and 2019 Q1 report. It states the company cannot complete the response by the original deadline and has applied for an extension. The document does not contain any financial data or the reports themselves, but is an announcement about the timing of a regulatory response related to filings. The length is only 553 characters, indicating it is a brief notice rather than a full report. Therefore, it fits best as a Regulatory Filing (RNS) since it is a compliance-related announcement that does not fit other categories and is not the report itself or a report publication announcement.
2019-04-29 Chinese
关于控股股东哈药集团增资扩股事宜的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a capital increase and share expansion by the controlling shareholder of the company, Harbin Pharmaceutical Group Co., Ltd. It details the board resolution, the proposed capital increase plan, conditions for completion, and potential changes in control. The document is a formal public disclosure of financing activity related to the company's controlling shareholder, focusing on capital structure changes and investment introduction. It does not contain financial statements or detailed financial performance data, nor is it a report or transcript. It is clearly an update on financing activities, fitting the Capital/Financing Update (CAP) category.
2019-04-24 Chinese
收到上海证券交易所关于对哈药集团股份有限公司2018年年度报告及2019年第一季度报告的事后审核问询函的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Harbin Pharmaceutical Group Co., Ltd. regarding a post-review inquiry letter from the Shanghai Stock Exchange about the company's 2018 Annual Report and 2019 Q1 Interim Report. The text contains detailed questions and requests for supplementary disclosures related to the company's financial performance, business operations, and accounting treatments. However, the document itself is not the annual report or the quarterly report but an official inquiry and request for additional information following the review of those reports. It is a regulatory announcement about the review process and the company's obligation to respond, not the report itself. The document length is about 4963 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the rules, this document should be classified as a Regulatory Filing (RNS), which is the fallback category for regulatory announcements and compliance documents that do not fit other specific categories.
2019-04-23 Chinese
独立董事关于会计政策变更的独立意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors regarding a change in accounting policies. It references compliance with accounting standards and regulatory bodies but does not contain financial statements or detailed financial data. The document is short (408 characters) and serves as an opinion or certification rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which includes officer certifications and attestations related to regulatory compliance.
2019-04-22 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.